Roche KRAS drug succeeds in head-to-head lung cancer study
Phase 3positivedivarasibPositive
AI Analysis
Summary
Roche's divarasib demonstrated success in a Phase 3 head-to-head trial against competing treatments from Amgen and Bristol Myers in patients with non-small cell lung cancer.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Divarasib succeeded in head-to-head comparison against Amgen and Bristol Myers treatments
Importance:8/10
Sentiment:
0.80
Phase 3 dataKRAS inhibitorlung cancerhead-to-head trialpositive results
Read the original article
Published by BioPharma Dive on July 2, 2026 2:19 PM